This study found that nearly 17 million adolescents and young adults were eligible for glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy. One in 5 young adults eligible for GLP-1RAs were ...

The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped ...

A cross-sectional analysis from Yale School of Medicine estimates that approximately 5.8 million adolescents and 11.1 million ...

Lexaria highlights DehydraTECH's adverse events improvement opportunity KELOWNA, BC / ACCESS Newswire / August 6, 2025 / ...

For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with ...

Results confirm previous findings that nonarteritic anterior ischemic optic neuropathy (NAION) was more likely in those who used semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA).

Glucagon-like peptide-1 (GLP-1) inhibitors have proven effective in preventing cardiovascular events, leading to experts ...

No difference in mortality risk seen for GLP-1 RA and SGLT2i users; significantly lower risk seen for GLP-1 RA versus DPP4i users.

Patients with type 2 diabetes, treated with GLP-1 receptor agonists, show a decreased risk of being diagnosed with ...

Most employees said health plans should cover GLP-1 medications, with 64% saying they should and 12% saying they should not.

Madrigal Pharmaceuticals Inc.’s long-awaited business development pact became reality by way of an exclusive global license agreement that could be worth more than $2 billion with CSPC Pharmaceutical ...

Medical professionals observe that GLP-1 medications like Ozempic show promise for treating rheumatoid arthritis alongside ...